Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
